191
Participants
Start Date
November 8, 2010
Primary Completion Date
November 5, 2012
Study Completion Date
November 5, 2012
GSK Biologicals HIV Vaccine 732462
2 or 3 doses according to protocol schedule
Placebo
1 or 3 doses according to protocol schedule
GSK Investigational Site, Berlin
GSK Investigational Site, Philadelphia
GSK Investigational Site, Philadelphia
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Annandale
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Móstoles, Madrid
GSK Investigational Site, Jacksonville
GSK Investigational Site, Orlando
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Johnson City
GSK Investigational Site, Columbus
GSK Investigational Site, Nantes
GSK Investigational Site, Bochum
GSK Investigational Site, Essen
GSK Investigational Site, Valencia
GSK Investigational Site, Omaha
GSK Investigational Site, Paris
GSK Investigational Site, Dallas
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Long Beach
GSK Investigational Site, Erlangen
GSK Investigational Site, Bobigny
GSK Investigational Site, Bakersfield
GSK Investigational Site, Créteil
GSK Investigational Site, Camden
GSK Investigational Site, Newark
GSK Investigational Site, Somers Point
GSK Investigational Site, Seattle
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY